Activator protein-1 binding activities in discrete regions of rat brain after acute and chronic administration of methamphetamine.
The activator protein-1 (AP-1) binding activities increased in three brain regions (striatum, nucleus accumbens, and cingulate cortex) after a single methamphetamine (METH) injection to rats. Pretreatment with SCH 23390, but not (-)-eticlopride, significantly inhibited the enhanced AP-1 binding activities induced by acute METH administration. The magnitude of enhancement of AP-1 binding activities 3 h after the last dose of chronic METH administration (4 mg/kg once daily for 14 days) was significantly attenuated as compared with those 3 h after a single METH administration. The AP-1 binding activities after a 1-, but not 4-, week abstinence from chronic administration of METH were still significantly higher than those of the saline-treated controls. A METH challenge after a 4-week abstinence period induced significantly lower AP-1 binding activities in rats chronically injected with METH than in rats chronically injected with saline. The supershift assay revealed that the levels of Jun family protein, but not Fos-related antigen, increased significantly in the striatum and nucleus accumbens of chronically METH-treated rats after a 1-week abstinence. These results suggest that chronic METH administration leads to delayed decay of the induced AP-1 binding activities and Jun component levels after abstinence for up to 1 week but results in no change in or decreases these activities and attenuates METH challenge-induced AP-1 binding activities after abstinence for 4 weeks.
Ishihara
T
T
Department of Neuropsychiatry, Okayama University Medical School, Japan.
Akiyama
K
K
Kashihara
K
K
Ujike
H
H
Hamamura
T
T
Okada
S
S
Kuroda
S
S
D000818:Animals; D001483:Base Sequence; D001552:Benzazepines / Q000494:pharmacology; D003342:Corpus Striatum / Q000196:embryology; D004268:DNA-Binding Proteins / Q000378:metabolism; D004334:Drug Administration Schedule; D051921:Fos-Related Antigen-2; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D008969:Molecular Sequence Data; D009714:Nucleus Accumbens / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012457:Salicylamides / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000502:physiology; D018808:Transcription Factor AP-1 / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism; D000099169:Fos-Related Antigen 1
D001552:Benzazepines; D004268:DNA-Binding Proteins; D051921:Fos-Related Antigen-2; D008694:Methamphetamine; D009838:Oligodeoxyribonucleotides; D016760:Proto-Oncogene Proteins c-fos; D012457:Salicylamides; D018808:Transcription Factor AP-1; D014157:Transcription Factors; D000099169:Fos-Related Antigen 1; C045989:eticlopride